Products
MORF4L1 antibody
- Product Name
- MORF4L1 antibody
- Catalogue No.
- FNab05273
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- mortality factor 4 like 1
- Alternative Names
- MRG15 antibody
- UniProt ID
- Q9UBU8
- Observed MW
- 35-37 kDa
Application
- Tested Applications
- ELISA, WB, IHC, IP
- Recommended dilution
- WB: 1:500-1:2000; IP: 1:200-1:1000; IHC: 1:20-1:200
Validated Images
HEK-293 cells were subjected to SDS PAGE followed by western blot with FNab05273(MORF4L1 antibody) at dilution of 1:500
IP Result of anti-MORF4L1 (IP:FNab05273, 4ug; Detection:FNab05273 1:800) with HEK-293 cells lysate 1200ug.
Immunohistochemistry of paraffin-embedded human skin using FNab05273(MORF4L1 antibody) at dilution of 1:100
- Background
- Component of the NuA4 histone acetyltransferase(HAT) complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome-DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when directly recruited to sites of DNA damage. Also component of the mSin3A complex which acts to repress transcription by deacetylation of nucleosomal histones. Required for homologous recombination repair(HRR) and resistance to mitomycin C(MMC). Involved in the localization of PALB2, BRCA2 and RAD51, but not BRCA1, to DNA-damage foci.
